Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]
Clinical trial NCT04564547 · COMPLETED
Trial details
- NCT number
- NCT04564547
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-03-09
- Primary completion
- 2025-01-30
- Enrollment
- 161
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.